By Colin Kellaher
Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic leukemia.
Eli Lilly on Friday said the recommendation covers Jaypirca for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a Bruton's tyrosine kinase inhibitor.
The Indianapolis drugmaker said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the next one to two months.
Eli Lilly previously won conditional European approval for Jaypirca in adults with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 28, 2025 08:59 ET (13:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.